This morning Allergy Therapeutics has announced it has completed enrolment with 364 patients in PQBirch204, its phase II randomised, double-blind placebo-controlled dose selection study for Pollinex Quattro Birch. The study is planned to complete by February 2016 with results available in Q2 2016 and should pave the way towards the start of the phase III study in 1Q17. We retain our investment thesis and repeat our Buy recommendation.
